Literature DB >> 2458151

Detection of minimal residual bcr/abl transcripts by a modified polymerase chain reaction.

M S Lee1, K S Chang, E J Freireich, H M Kantarjian, M Talpaz, J M Trujillo, S A Stass.   

Abstract

The Philadelphia (Ph1) chromosome in chronic myelogenous leukemia (CML) involves reciprocal translocation of the bcr gene and the c-abl oncogene. The fused bcr/abl gene is transcribed into two types of chimeric mRNA. By means of a combined method of S1 nuclease protection and polymerase chain reaction, we amplified sequences representative of the chimeric bcr/abl transcripts. Only 5 micrograms of total cellular RNA is needed and the chimeric bcr/abl message can be detected at a dilution of 1:100,000. We also detected residual chimeric bcr/abl transcripts in the remission samples from two Ph1-positive CML patients. This technique has the potential to identify a subpopulation of Ph1-positive CML patients in remission who are at high risk of relapse.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2458151

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Polymerase chain reaction based assay to detect allelic loss in human DNA: loss of beta-interferon gene in chronic myelogenous leukemia.

Authors:  A Neubauer; B Neubauer; E Liu
Journal:  Nucleic Acids Res       Date:  1990-02-25       Impact factor: 16.971

Review 2.  Polymerase chain reaction.

Authors:  H A Erlich
Journal:  J Clin Immunol       Date:  1989-11       Impact factor: 8.317

Review 3.  Interferon in chronic myeloid leukemia. A workshop report.

Authors:  M Griesshammer; R Hehlmann; A Hochhaus; M Talpaz; S Tura; P Stryckmans; N C Allan; J Tanzer; H J Kolb; H Heimpel
Journal:  Ann Hematol       Date:  1993-08       Impact factor: 3.673

4.  Sequence analysis of polymerase chain reaction amplified t(14;18) chromosomal breakpoints in formalin fixed, paraffin wax embedded follicular lymphoma.

Authors:  M Volkenandt; O Koch; R Fanin; D Banerjee; A Seger; J Vogel; E Bierhoff; G Heidl; L Neyses; J R Bertino
Journal:  J Clin Pathol       Date:  1992-03       Impact factor: 3.411

5.  Detection of minimal disease in hematopoietic malignancies of the B-cell lineage by using third-complementarity-determining region (CDR-III)-specific probes.

Authors:  M Yamada; S Hudson; O Tournay; S Bittenbender; S S Shane; B Lange; Y Tsujimoto; A J Caton; G Rovera
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

6.  Fine mapping of chromosome 22 breakpoints within the breakpoint cluster region (bcr) implies a role for bcr exon 3 in determining disease duration in chronic myeloid leukemia.

Authors:  A Grossman; R T Silver; Z Arlin; M Coleman; E Camposano; P Gascon; P A Benn
Journal:  Am J Hum Genet       Date:  1989-11       Impact factor: 11.025

Review 7.  Re-emergence of interferon-α in the treatment of chronic myeloid leukemia.

Authors:  M Talpaz; R Hehlmann; A Quintás-Cardama; J Mercer; J Cortes
Journal:  Leukemia       Date:  2012-11-07       Impact factor: 11.528

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.